|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
4
|
|
pubmed:dateCreated |
2003-4-28
|
|
pubmed:abstractText |
Isolated limb perfusion (ILP) with tumor necrosis factor-alpha (TNF) and melphalan for advanced extremity malignancies achieves significant complete response rates. To study molecular mechanisms underlying this response, a nude rat ILP model with a human melanoma xenograft was developed.
|
|
pubmed:grant |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Apr
|
|
pubmed:issn |
0039-6060
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
133
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
420-8
|
|
pubmed:dateRevised |
2007-11-14
|
|
pubmed:meshHeading |
pubmed-meshheading:12717360-Animals,
pubmed-meshheading:12717360-Antineoplastic Agents,
pubmed-meshheading:12717360-Antineoplastic Agents, Alkylating,
pubmed-meshheading:12717360-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:12717360-Disease Models, Animal,
pubmed-meshheading:12717360-Female,
pubmed-meshheading:12717360-Hindlimb,
pubmed-meshheading:12717360-Humans,
pubmed-meshheading:12717360-Melanoma,
pubmed-meshheading:12717360-Melphalan,
pubmed-meshheading:12717360-Perfusion,
pubmed-meshheading:12717360-Rats,
pubmed-meshheading:12717360-Rats, Nude,
pubmed-meshheading:12717360-Skin Neoplasms,
pubmed-meshheading:12717360-Tumor Cells, Cultured,
pubmed-meshheading:12717360-Tumor Necrosis Factor-alpha,
pubmed-meshheading:12717360-Xenograft Model Antitumor Assays
|
|
pubmed:year |
2003
|
|
pubmed:articleTitle |
A human melanoma xenograft in a nude rat responds to isolated limb perfusion with TNF plus melphalan.
|
|
pubmed:affiliation |
Division of Surgical Oncology, Department of Surgery, Hospital of the University of Pennsylvania, 3400 Spruce Street, Philadelphia, PA 19104, USA.
|
|
pubmed:publicationType |
Journal Article,
Research Support, U.S. Gov't, P.H.S.,
Research Support, Non-U.S. Gov't
|
